ModernaThursday’s Covid-19 vaccination was defended by the FDA. The vaccine offers protection against serious disease, hospitalization, and death. It also reduces myocarditis risk, which is a rare condition that affects a few young men.

The company said last week that the Food and Drug Administration required more time in order to determine whether it would approve the two-dose vaccine. It was doing so while the agency investigates reports of myocarditis or inflammation of the heart muscle.

The number of cases reported by Moderna for rare and severe heart inflammation among men younger than 30 years old is significantly higher when they have received Moderna’s vaccination, compared to those who had the shot made by Pfizer BioNTechPaul Burton, Moderna’s chief medical officer, said this to reporters in a telephone call.

Burton referenced data from France about males aged 12-19 years. This data showed that Moderna’s vaccine caused 13.3 cases of myocarditis in 100,000 people, while the Pfizer vaccine only caused 2.7.

He also cited data from the Centers for Disease Control and Prevention, which showed that the rate of Covid-related mild and severe diseases were lower among Moderna recipients than those who had received Pfizer. Johnson & Johnson’s vaccine.

On the phone, he stated that “while I feel health authorities are cautiously assessing the data but continuing to recommend the use mRNA-1273 Moderna vaccin”, he added. He added that he believes the benefit-risk ratio is very favorable.

This story is still in development. Keep checking back for more updates.